Incyte Corp. buy stratec
Start price
19.02.20
/
50%
€75.44
Target price
04.11.21
€100.00
Performance (%)
-22.53%
End price
05.11.21
€58.44
Summary
This prediction ended on 05.11.21 with a price of €58.44. The price of Incyte Corp. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -22.53%. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Incyte Corp. | 3.998% | 3.998% | 57.115% | 86.386% |
| iShares Core DAX® | 1.014% | 2.699% | 4.363% | 51.689% |
| iShares Nasdaq 100 | -6.470% | -8.771% | 18.004% | 67.992% |
| iShares Nikkei 225® | -6.517% | -12.580% | 40.915% | 57.109% |
| iShares S&P 500 | -2.721% | -1.752% | 16.966% | 58.872% |
Comments by stratec for this prediction
In the thread Incyte Corp. diskutieren
Incyte (NASDAQ:INCY) perks up 2% premarket on light volume on the heels of its announcement of positive results from a second Phase 3 clinical trial, TRuE-AD1, evaluating ruxolitinib cream 0.75% or 1.5% in patients at least 12 years old with mild-to-moderate atopic dermatitis (AD). The study met the primary endpoint of a statistically significant proportion of treated patients achieving clear or almost clear skin at week 8 compared to vehicle (placebo). A sister Phase 3, TRuE-AD2, was also successful. Marketing applications should be the next step.
Kursziel geändert auf 100,0
In the thread Trading Incyte Corp.
Die von stratec gewählte maximale Laufzeit wurde überschritten